Summary
Global Markets Direct’s, ‘Allergic Rhinitis - Pipeline Review, H1 2016’, provides an overview of the Allergic Rhinitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis
- The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects
- The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
3M Drug Delivery Systems
Accolade Pharmaceuticals, LLC
Adamis Pharmaceuticals Corporation
AFFiRiS AG
ALK-Abello A/S
Ampio Pharmaceuticals, Inc.
AnaptysBio, Inc.
ASIT biotech s.a.
Axikin Pharmaceuticals, Inc.
Chong Kun Dang Pharmaceutical Corp.
Chrysalis BioTherapeutics, Inc.
ELORAC, Inc.
Faes Farma, SA
Fountain Biopharma Inc.
GenMont Biotech Inc.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
HAL Allergy BV
Hanmi Pharmaceuticals, Co. Ltd.
Hisamitsu Pharmaceutical Co., Inc.
J Uriach Y Compania, S.A.
Johnson & Johnson
Laboratorios LETI S.L.
Ligand Pharmaceuticals, Inc.
Marinomed Biotechnologie GmbH
Merck & Co., Inc.
Panmira Pharmaceuticals, LLC.
Pfizer Inc.
Protectimmun GmbH
Regeneron Pharmaceuticals, Inc.
RODES Inc.
Roxall Medizin GmbH
Sanofi
Shionogi & Co., Ltd.
Stallergenes SAS
Taiho Pharmaceutical Co., Ltd.
VentiRx Pharmaceuticals, Inc.
Xencor, Inc.
Ziarco Pharma Ltd
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Allergic Rhinitis Overview 10
Therapeutics Development 11
Pipeline Products for Allergic Rhinitis - Overview 11
Pipeline Products for Allergic Rhinitis - Comparative Analysis 12
Allergic Rhinitis - Therapeutics under Development by Companies 13
Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 16
Allergic Rhinitis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Allergic Rhinitis - Products under Development by Companies 20
Allergic Rhinitis - Products under Investigation by Universities/Institutes 25
Allergic Rhinitis - Companies Involved in Therapeutics Development 26
3M Drug Delivery Systems 26
Accolade Pharmaceuticals, LLC 27
Adamis Pharmaceuticals Corporation 28
AFFiRiS AG 29
ALK-Abello A/S 30
Ampio Pharmaceuticals, Inc. 31
AnaptysBio, Inc. 32
ASIT biotech s.a. 33
Axikin Pharmaceuticals, Inc. 34
Chong Kun Dang Pharmaceutical Corp. 35
Chrysalis BioTherapeutics, Inc. 36
ELORAC, Inc. 37
Faes Farma, SA 38
Fountain Biopharma Inc. 39
GenMont Biotech Inc. 40
GlaxoSmithKline Plc 41
Glenmark Pharmaceuticals Ltd. 42
HAL Allergy BV 43
Hanmi Pharmaceuticals, Co. Ltd. 44
Hisamitsu Pharmaceutical Co., Inc. 45
J Uriach Y Compania, S.A. 46
Johnson & Johnson 47
Laboratorios LETI S.L. 48
Ligand Pharmaceuticals, Inc. 49
Marinomed Biotechnologie GmbH 50
Merck & Co., Inc. 51
Panmira Pharmaceuticals, LLC. 52
Pfizer Inc. 53
Protectimmun GmbH 54
Regeneron Pharmaceuticals, Inc. 55
RODES Inc. 56
Roxall Medizin GmbH 57
Sanofi 58
Shionogi & Co., Ltd. 59
Stallergenes SAS 60
Taiho Pharmaceutical Co., Ltd. 61
VentiRx Pharmaceuticals, Inc. 62
Xencor, Inc. 63
Ziarco Pharma Ltd 64
Allergic Rhinitis - Therapeutics Assessment 65
Assessment by Monotherapy Products 65
Assessment by Combination Products 66
Assessment by Target 67
Assessment by Mechanism of Action 69
Assessment by Route of Administration 71
Assessment by Molecule Type 73
Drug Profiles 75
(azelastine hydrochloride + budesonide) - Drug Profile 75
(fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile 77
(fluticasone furoate + levocabastine hydrochloride) - Drug Profile 78
(levocabastine hydrochloride + mometasone furoate) - Drug Profile 79
(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 80
Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile 81
Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 82
Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 83
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 84
Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 85
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 86
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 88
Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 89
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 91
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 92
AM-211 - Drug Profile 93
AM-461 - Drug Profile 95
Ampion - Drug Profile 96
ANB-020 - Drug Profile 98
APC-3000 - Drug Profile 99
Arabinogalactan - Drug Profile 100
asapiprant - Drug Profile 101
beta-escin - Drug Profile 102
bilastine - Drug Profile 103
budesonide - Drug Profile 106
CBP-174 - Drug Profile 107
cidoxepin hydrochloride - Drug Profile 108
clustoid wiesenlieschgras - Drug Profile 109
desloratadine - Drug Profile 110
Drugs to Inhibit PIM-1 Kinase for Respiratory and Immunological Diseases - Drug Profile 112
emedastine difumarate - Drug Profile 113
esketamine hydrochloride - Drug Profile 114
FB-825 - Drug Profile 117
GMNL-32 - Drug Profile 118
gp-ASIT - Drug Profile 119
GSK-2245035 - Drug Profile 121
GSP-301 - Drug Profile 123
Lactococcus lactis G121 - Drug Profile 124
motolimod - Drug Profile 125
nasapaque - Drug Profile 127
pentosan polysulfate sodium - Drug Profile 128
PF-06444752 - Drug Profile 129
PF-06444753 - Drug Profile 131
rE58 - Drug Profile 132
REGN-19081909 - Drug Profile 133
rupatadine - Drug Profile 134
Small Molecule for Allergic Rhinitis - Drug Profile 135
Small Molecule to Agonize TLR-7 and TLR-8 for Oncology, Allergic Rhinitis, Actinic Keratosis and Warts - Drug Profile 136
Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 137
Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile 138
Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 139
Small Molecules to Inhibit Spleen Tyrosine Kinase for Allergic Inflammatory Disorders - Drug Profile 140
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 141
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 143
STG-120 - Drug Profile 146
TAS-205 - Drug Profile 147
Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile 148
VTX-1463 - Drug Profile 149
XmAb-7195 - Drug Profile 150
Zafi-3 - Drug Profile 151
ZPL-868087 - Drug Profile 152
Allergic Rhinitis - Recent Pipeline Updates 153
Allergic Rhinitis - Dormant Projects 173
Allergic Rhinitis - Discontinued Products 182
Allergic Rhinitis - Product Development Milestones 185
Featured News & Press Releases 185
Appendix 192
Methodology 192
Coverage 192
Secondary Research 192
Primary Research 192
Expert Panel Validation 192
Contact Us 192
Disclaimer 193
List of Tables
Number of Products under Development for Allergic Rhinitis, H1 2016 15
Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Number of Products under Development by Companies, H1 2016 (Contd..1) 18
Number of Products under Development by Companies, H1 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Late Stage Development, H1 2016 21
Comparative Analysis by Clinical Stage Development, H1 2016 22
Comparative Analysis by Early Stage Development, H1 2016 23
Products under Development by Companies, H1 2016 24
Products under Development by Companies, H1 2016 (Contd..1) 25
Products under Development by Companies, H1 2016 (Contd..2) 26
Products under Development by Companies, H1 2016 (Contd..3) 27
Products under Development by Companies, H1 2016 (Contd..4) 28
Products under Investigation by Universities/Institutes, H1 2016 29
Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H1 2016 30
Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals, LLC, H1 2016 31
Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016 32
Allergic Rhinitis - Pipeline by AFFiRiS AG, H1 2016 33
Allergic Rhinitis - Pipeline by ALK-Abello A/S, H1 2016 34
Allergic Rhinitis - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 35
Allergic Rhinitis - Pipeline by AnaptysBio, Inc., H1 2016 36
Allergic Rhinitis - Pipeline by ASIT biotech s.a., H1 2016 37
Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H1 2016 38
Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 39
Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics, Inc., H1 2016 40
Allergic Rhinitis - Pipeline by ELORAC, Inc., H1 2016 41
Allergic Rhinitis - Pipeline by Faes Farma, SA, H1 2016 42
Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H1 2016 43
Allergic Rhinitis - Pipeline by GenMont Biotech Inc., H1 2016 44
Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H1 2016 45
Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 46
Allergic Rhinitis - Pipeline by HAL Allergy BV, H1 2016 47
Allergic Rhinitis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 48
Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 49
Allergic Rhinitis - Pipeline by J Uriach Y Compania, S.A., H1 2016 50
Allergic Rhinitis - Pipeline by Johnson & Johnson, H1 2016 51
Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H1 2016 52
Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 53
Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2016 54
Allergic Rhinitis - Pipeline by Merck & Co., Inc., H1 2016 55
Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H1 2016 56
Allergic Rhinitis - Pipeline by Pfizer Inc., H1 2016 57
Allergic Rhinitis - Pipeline by Protectimmun GmbH, H1 2016 58
Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 59
Allergic Rhinitis - Pipeline by RODES Inc., H1 2016 60
Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H1 2016 61
Allergic Rhinitis - Pipeline by Sanofi, H1 2016 62
Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H1 2016 63
Allergic Rhinitis - Pipeline by Stallergenes SAS, H1 2016 64
Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 65
Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016 66
Allergic Rhinitis - Pipeline by Xencor, Inc., H1 2016 67
Allergic Rhinitis - Pipeline by Ziarco Pharma Ltd, H1 2016 68
Assessment by Monotherapy Products, H1 2016 69
Assessment by Combination Products, H1 2016 70
Number of Products by Stage and Target, H1 2016 72
Number of Products by Stage and Mechanism of Action, H1 2016 74
Number of Products by Stage and Route of Administration, H1 2016 76
Number of Products by Stage and Molecule Type, H1 2016 78
Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H1 2016 157
Allergic Rhinitis - Dormant Projects, H1 2016 177
Allergic Rhinitis - Dormant Projects (Contd..1), H1 2016 178
Allergic Rhinitis - Dormant Projects (Contd..2), H1 2016 179
Allergic Rhinitis - Dormant Projects (Contd..3), H1 2016 180
Allergic Rhinitis - Dormant Projects (Contd..4), H1 2016 181
Allergic Rhinitis - Dormant Projects (Contd..5), H1 2016 182
Allergic Rhinitis - Dormant Projects (Contd..6), H1 2016 183
Allergic Rhinitis - Dormant Projects (Contd..7), H1 2016 184
Allergic Rhinitis - Dormant Projects (Contd..8), H1 2016 185
Allergic Rhinitis - Discontinued Products, H1 2016 186
Allergic Rhinitis - Discontinued Products (Contd..1), H1 2016 187
Allergic Rhinitis - Discontinued Products (Contd..2), H1 2016 188
List of Figures
Number of Products under Development for Allergic Rhinitis, H1 2016 15
Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Late Stage Development, H1 2016 21
Comparative Analysis by Clinical Stage Development, H1 2016 22
Comparative Analysis by Early Stage Products, H1 2016 23
Assessment by Monotherapy Products, H1 2016 69
Assessment by Combination Products, H1 2016 70
Number of Products by Top 10 Targets, H1 2016 71
Number of Products by Stage and Top 10 Targets, H1 2016 71
Number of Products by Top 10 Mechanism of Actions, H1 2016 73
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 73
Number of Products by Top 10 Routes of Administration, H1 2016 75
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 75
Number of Products by Molecule Types, H1 2016 77
Number of Products by Stage and Molecule Types, H1 2016 77
